https://doi.org/10.4081/monaldi.2024.3029
A decade’s summary of transcatheter tricuspid valve repair
Submitted: April 15, 2024
Accepted: July 12, 2024
Published: July 25, 2024
Accepted: July 12, 2024
Abstract Views: 3795
PDF_EARLY VIEW: 126
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Tricuspid regurgitation (TR) is the most common pathology for the tricuspid valve. Moderate to severe TR is associated with morbidity and adverse outcomes. The concept that TR resolves on its own if the underlying disease is successfully treated has proven to be false. Only a few patients with significant TR are deemed suitable for surgery. Given the late presentation of patients with high perioperative risks and substantial perioperative mortality, the development of transcatheter therapies and the experience gained with transcatheter aortic valve implantation operations have turned attention towards treating this challenging group of patients. In this article, we review the treatment options and highlight the role of transcatheter valve therapies in patients with severe TR.
Fender EA, Zack CJ, Nishimura RA. Isolated tricuspid regurgitation: outcomes and therapeutic interventions. Heart 2018;104:798-806.
DOI: https://doi.org/10.1136/heartjnl-2017-311586
Taramasso M, Gavazzoni M, Pozzoli A, et al. Outcomes of TTVI in patients with pacemaker or defibrillator leads: data from the trivalve registry. JACC 2020;13:554-64.
DOI: https://doi.org/10.1016/j.jcin.2019.10.058
Prihadi EA. Tricuspid valve regurgitation: no longer the ‘forgotten valve. J Cardiol Pract 2018;16.
Kirklin JK, Blackstone EH. Kirklin/Barratt-Boyes Cardiac Surgery. Amsterdam: Elsevier Health Sciences; 2012.
Izumi C, Miyake M, Takahashi S, et al. Progression of isolated tricuspid regurgitation late after mitral valve surgery for rheumatic mitral valve disease. J Heart Valve Dis 2022;11:353-6.
Porter A, Shapira Y, Wurzel M, et al. Tricuspid regurgitation late after mitral valve replacement: clinical and echocardiographic evaluation. J Heart Valve Dis 1999;8:57-62.
Matsunaga A, Duran CMG. Progression of tricuspid regurgitation after repaired functional ischemic mitral regurgitation. Circulation 2005;112:I453-7.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.104.524421
De Bonis M, Lapenna E, Sorrentino F, et al. Evolution of tricuspid regurgitation after mitral valve repair for functional mitral regurgitation in dilated cardiomyopathy. Eur J Cardiothorac Surg 2008;33:600-6.
DOI: https://doi.org/10.1016/j.ejcts.2008.01.011
Alfieri O, Maisano F. An effective technique to correct anterior mitral leaflet prolapse. J Card Surg 1999;14:468-70.
DOI: https://doi.org/10.1111/j.1540-8191.1999.tb01280.x
Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol 2004;43:405-9.
DOI: https://doi.org/10.1016/j.jacc.2003.09.036
Chorin E, Rozenbaum Z, Topilsky Y, et al. Tricuspid regurgitation and long-term clinical outcomes. Eur Heart J Cardiovasc Imaging 2020;21:157.65.
DOI: https://doi.org/10.1093/ehjci/jez216
De la Espriella R, Santas E, Chorro FJ, et al. Functional tricuspid regurgitation and recurrent admissions in patients with acute heart failure. Int J Cardiol 2019;291:83-8.
DOI: https://doi.org/10.1016/j.ijcard.2019.03.051
Besler C, Seeburger J, Thiele H, Lurz P. Treatment options for severe functional tricuspid regurgitation: indications, techniques and current challenges. ESC Eur J Cardiol Pract 2018;16.
Dreyfus GD, Corbi PJ, Chan KMJ, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criteria for surgical repair?. Ann Thorac Surg 2005;79:127-32.
DOI: https://doi.org/10.1016/j.athoracsur.2004.06.057
Van de Veire NR, Braun J, Delgado V, et al. Tricuspid annuloplasty prevents right ventricular dilatation and progression of tricuspid regurgitation in patients with tricuspid annular dilatation undergoing mitral valve repair. J Thorac Cardiovasc Surg 2011;141:1431-9.
DOI: https://doi.org/10.1016/j.jtcvs.2010.05.050
Chikwe J, Itagaki S, Anyanwu A, Adams DH. Impact of concomitant tricuspid annuloplasty on tricuspid regurgitation, right ventricular function, and pulmonary artery hypertension after repair of mitral valve prolapse. J Am Coll Cardiol 2015;65:1931-8.
DOI: https://doi.org/10.1016/j.jacc.2015.01.059
Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2022;43:561-632.
DOI: https://doi.org/10.1093/eurheartj/ehac051
Lauten A, Ferrari M, Hekmat K, et al. Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation. Eur Heart J 2011;32:1207-13.
DOI: https://doi.org/10.1093/eurheartj/ehr028
Schueler R, Hammerstingl C, Werner N, Nickenig G. Interventional direct annuloplasty for functional tricuspid regurgitation. JACC Cardiovasc Interv 2017;10:415-6.
DOI: https://doi.org/10.1016/j.jcin.2016.10.033
Hahn RT, George I, Kodali SK, et al. Early single-site experience with transcatheter tricuspid valve replacement. JACC Cardiovasc Imaging 2019;12:416-29.
DOI: https://doi.org/10.1016/j.jcmg.2018.08.034
Taramasso M, Hahn RT, Alessandrini H, et al. The international multicenter TriValve registry: which patients are undergoing transcatheter tricuspid repair?. JACC Cardiovasc Interv 2017;10:1982-990.
DOI: https://doi.org/10.1016/j.jcin.2017.08.011
Taramasso M, Alessandrini H, Latib A, et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international TriValve registry. JACC Cardiovasc Interv 2019;12:155-65.
DOI: https://doi.org/10.1016/j.jcin.2018.10.022
Besler C, Orban M, Rommel KR, et al. Predictors of procedural and clinical outcomes in patients with symptomatic tricuspid regurgitation undergoing transcatheter edge-to-edge repair. JACC Cardiovasc Interv 2018;11:1119-28.
DOI: https://doi.org/10.1016/j.jcin.2018.05.002
Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet 2019;394:2002-11.
DOI: https://doi.org/10.1016/S0140-6736(19)32600-5
Mehr M, Taramasso M, Besler C, et al. 1-Year outcomes after edge-to-edge valve repair for symptomatic tricuspid regurgitation: results from the TriValve registry. JACC Cardiovasc Interv 2019;12:1451-61.
DOI: https://doi.org/10.1016/j.jcin.2019.04.019
Praz F, Spargias K, Chrissoheris M, et al. Compassionate use of the PASCAL transcatheter mitral valve repair system for patients with severe mitral regurgitation: a multicentre, prospective, observational, first-in-man study. Lancet 2017;390:773-80.
DOI: https://doi.org/10.1016/S0140-6736(17)31600-8
Scott Lim D, Kar S, Spargias K, et al. Transcatheter valve repair for patients with mitral regurgitation: 30-day results of the CLASP study. JACC Cardiovasc Interv 2019;12:1369-78.
DOI: https://doi.org/10.1016/j.jcin.2019.04.034
Fam NP, Braun D, von Bardeleben RS, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv 2019;12:2488-95.
DOI: https://doi.org/10.1016/j.jcin.2019.09.046
Wild MG, Löw K, Rosch S, et al. Multicenter experience with the transcatheter leaflet repair system for symptomatic tricuspid regurgitation. JACC Cardiovasc Interv 2022;15:1352-63.
DOI: https://doi.org/10.1016/j.jcin.2022.05.041
Puri R, Rodés-Cabau J. Transcatheter interventions for tricuspid regurgitation: the FORMA repair system. Interv Cardiol Clin 2018;7:47-55.
DOI: https://doi.org/10.1016/j.iccl.2017.08.007
Perlman G, Praz F, Puri R, et al. Transcatheter tricuspid valve repair with a new transcatheter coaptation system for the treatment of severe tricuspid regurgitation: 1-year clinical and echocardiographic results. JACC Cardiovasc Interv 2017;10:1994-2003.
DOI: https://doi.org/10.1016/j.jcin.2017.06.036
Asmarats L, Perlman G, Praz F, et al. Long-term outcomes of the FORMA transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation: insights from the first-in-human experience. JACC Cardiovasc Interv 2019;12:1438-47.
DOI: https://doi.org/10.1016/j.jcin.2019.04.038
van Rosendael PJ, Delgado V, Bax JJ. The tricuspid valve and the right heart: anatomical, pathological and imaging specifications. EuroIntervention 2015;11:W123-7.
DOI: https://doi.org/10.4244/EIJV11SWA35
Siminiak T, Dankowski R, Baszko A, et al. Percutaneous direct mitral annuloplasty using the Mitralign BidentTM system: description of the method and a case report. Kardiol Pol 2013;71:1287-92.
DOI: https://doi.org/10.5603/KP.2013.0325
Besler C, Meduri CU, Lurz P. Transcatheter treatment of functional tricuspid regurgitation using the trialign device. Interv Cardiol 2018;13:8-13.
DOI: https://doi.org/10.15420/icr.2017:21:1
Latib A, Agricola E, Pozzoli A, et al. First-in-man implantation of a tricuspid annular remodeling device for functional tricuspid regurgitation. JACC Cardiovasc Interv 2015;8:e211-4.
DOI: https://doi.org/10.1016/j.jcin.2015.06.028
Mangieri A, Latib A. Transcatheter innovations in tricuspid regurgitation: cardioband. Prog Cardiovasc Dis 2019;62:482-5.
DOI: https://doi.org/10.1016/j.pcad.2019.10.002
von Bardeleben RS, Ruf T, Schulz E, et al. First percutaneous COMBO therapy of tricuspid regurgitation using direct annuloplasty and staged edge-to-edge repair in a surgical-like Clover technique. Eur Heart J 2018;39:3621-2.
DOI: https://doi.org/10.1093/eurheartj/ehy536
Lauten A, Figulla HR, Unbehaun A, et al. Interventional treatment of severe tricuspid regurgitation: early clinical experience in a multicenter, observational, first-in-man study. Circ Cardiovasc Interv 2018;11:e006061.
DOI: https://doi.org/10.1161/CIRCINTERVENTIONS.117.006061
Liu Y, Li W, Zhou D, et al. Step-by-step transesophageal echocardiographic guidance for transjugular transcatheter tricuspid valve replacement with a radial force-independent bioprosthesis. Quant Imaging Med Surg 2024;14:1061-9.
DOI: https://doi.org/10.21037/qims-23-218
Mao Y, Li L, Liu Y, et al. Safety, efficacy, and clinical outcomes of transcatheter tricuspid valve replacement: one-year follow-up. Front Cardiovasc Med 2022;9:1019813.
DOI: https://doi.org/10.3389/fcvm.2022.1019813
S. Kodali et al., “Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study,” Eur Heart J, vol. 44, no. 46, pp. 4862–4873, 2023.
Aboulhosn J, Cabalka AK, Levi DS, et al. Transcatheter valve-in-ring implantation for the treatment of residual or recurrent tricuspid valve dysfunction after prior surgical repair. JACC Cardiovasc Interv 2017;10:53-63.
DOI: https://doi.org/10.1016/j.jcin.2016.10.036
Mao Y, Liu Y, Meng X, et al. Treatment of severe tricuspid regurgitation induced by permanent pacemaker lead: transcatheter tricuspid valve replacement with the guidance of 3-dimensional printing. Front Cardiovasc Med 2023;10:1030997.
DOI: https://doi.org/10.3389/fcvm.2023.1030997
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018;39:3165-241.
DOI: https://doi.org/10.1093/eurheartj/ehy478
Orban M, Rommel KP, Ho EC, et al. Transcatheter edge-to-edge tricuspid repair for severe tricuspid regurgitation reduces hospitalizations for heart failure. JACC Heart Fail 2020;8:265-76.
DOI: https://doi.org/10.1016/j.jchf.2019.12.006
Kresoja KP, Lauten A, Orban M, et al. Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction. Eur J Heart Fail 2020;22:1817-25.
DOI: https://doi.org/10.1002/ejhf.1975
Rommel KP, Besler C, Noack T, et al. Physiological and clinical consequences of right ventricular volume overload reduction after transcatheter treatment for tricuspid regurgitation. JACC Cardiovasc Interv 2019;12:1423-34.
DOI: https://doi.org/10.1016/j.jcin.2019.02.042
Lurz P, Giardini A, Taylor AM, et al. Effect of altering pathologic right ventricular loading conditions by percutaneous pulmonary valve implantation on exercise capacity. Am J Cardiol 2010;105:721-6.
DOI: https://doi.org/10.1016/j.amjcard.2009.10.054
Lyle Dershowitz 1, Lawlor MK, Hamid N, et al. Right ventricular remodeling and clinical outcomes following transcatheter tricuspid valve intervention. Catheter Cardiovasc Interv 2024;103:367-75.
DOI: https://doi.org/10.1002/ccd.30850
Rudski LG, Afilalo J. Right ventricle-pulmonary artery coupling in percutaneous tricuspid valve repair: is simple sufficient?. J Am Coll Cardiol 2022;79:462-4.
DOI: https://doi.org/10.1016/j.jacc.2021.11.030
Wu Z, Zhu W, Kaisaier W, et al. Periprocedural, short-term, and long-term outcomes following transcatheter tricuspid valve repair: a systemic review and meta-analysis. Ther Adv Chronic Dis 2023;20406223231158610.
DOI: https://doi.org/10.1177/20406223231158607
Ethics Approval
The study protocol was approved by the Audit, Assurance & Effectiveness Team of the University Hospitals of Plymouth. (protocol no. CA_2021- 22-120 dated 17/09/2021).How to Cite
Bashir, Aladdin, Zaheer Tahir, Mahmood Ahmad, Kyriacos Mouyis, Ali Zuhair Kirresh, Sameh Atta, Clinton Lloyd, and Malcolm Dalrymple-Hay. 2024. “A decade’s Summary of Transcatheter Tricuspid Valve Repair”. Monaldi Archives for Chest Disease, July. https://doi.org/10.4081/monaldi.2024.3029.
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- M. Marvisi, L. Balzarini, C. Mancini, P. Mouzakiti, A new type of Hypersensitivity Pneumonitis: salami brusher’s disease , Monaldi Archives for Chest Disease: Vol. 77 No. 1 (2012): Pulmonary series
- S. La Grutta, G. Nicolini, C. Capristo, S.C. Bellodi, G.A. Rossi, Once daily nebulized beclomethasone is effective in maintaining pulmonary function and improving symptoms in asthmatic children , Monaldi Archives for Chest Disease: Vol. 67 No. 1 (2007): Pulmonary series
- I. Chkhaidze, T. Maglakelidze, N. Khaltaev, Chronic respiratory diseases at primary health care level in Georgia: the results of the pilot study , Monaldi Archives for Chest Disease: Vol. 71 No. 4 (2009): Pulmonary series
- Enrico Vassallo, Francesca Musella, Susanna Mosca, Laura Casaretti, Roberto Formisano, Giacomo Mattiello, Ada Bologna, Irma Fabiani, Francesco Gambardella, Laura Petraglia, Giuseppe Rengo, Dario Leosco, Pasquale Perrone-Filardi, Clinical and therapeutic value of carotid intima-media thickness , Monaldi Archives for Chest Disease: Vol. 76 No. 3 (2011): Cardiac series
- R.W. Dal Negro, B. Balbi, A. Spanevello, Monaldi Archives for Chest Disease enters Clinical Pharmacology officially , Monaldi Archives for Chest Disease: Vol. 71 No. 3 (2009): Pulmonary series
- A. Zanini, S. Della Patrona, A.L. Facchini, A. Spanevello, Induced sputum in the management of COPD: clinical implications , Monaldi Archives for Chest Disease: Vol. 77 No. 1 (2012): Pulmonary series
- M. Confalonieri, M. Kodric, M. Santagiuliana, C. Longo, M. Biolo, R. Cifaldi, C. Torregiani, M. Jevnikar, To use or not to use corticosteroids for pneumonia? A clinician’s perspective , Monaldi Archives for Chest Disease: Vol. 77 No. 2 (2012): Pulmonary series
- Furio Colivicchi, From warfarin to new oral anticoagulants in clinical practice. What is the future of anticoagulant therapy in atrial fibrillation? , Monaldi Archives for Chest Disease: Vol. 80 No. 2 (2013): Cardiac series
- B. Balbi, M. Luisetti, L. Corda, N. Gatta, Alpha-1 antitrypsin deficiency: from Italy to the world , Monaldi Archives for Chest Disease: Vol. 67 No. 4 (2007): Pulmonary series
- G.B. Migliori, R. Centis, C. Lange, A. Matteelli, D. Cirillo, Tuberculosis, one disease, many faces , Monaldi Archives for Chest Disease: Vol. 69 No. 1 (2008): Pulmonary series
<< < 53 54 55 56 57 58 59 60 61 62 > >>
You may also start an advanced similarity search for this article.
